Verastem’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Verastem is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer. Read more

Brian Stuglik's photo - CEO of Verastem

CEO

Brian Stuglik

CEO Approval Rating

66/100

Founded:

2010

Status:

PublicNASDAQVSTM

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

TG Therapeutics is the biggest rival of Verastem. TG Therapeutics is headquartered in New York, New York, and was founded in 1993. Like Verastem, TG Therapeutics also operates in the Pharmaceuticals space. TG Therapeutics generates 0.69% the revenue of Verastem.

MEI Pharma is Verastem's #2 competitor. MEI Pharma is a Public company that was founded in San Diego, California in 2000. Like Verastem, MEI Pharma also works within the Pharmaceuticals sector. MEI Pharma has 118 fewer employees vs. Verastem.

Pharmacyclics has been one of Verastem's top competitors. Pharmacyclics's headquarters is in Sunnyvale, California, and was founded in 1991. Pharmacyclics operates in the Pharmaceuticals industry. Pharmacyclics generates 3,553% of Verastem's revenue.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is ZYDELIG a competitor of Verastem?

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$22M

Verastem's revenue is the ranked 7th among it's top 10 competitors. The top 10 competitors average 85M. Over the last four quarters, Verastem's revenue has decreased by 52.3%. Specifically, in Q2 2020's revenue was $4.3M; in Q1 2020, it was $5.1M; in Q4 2019, it was $3.6M; in Q3 2019, Verastem's revenue was $9M.

Acquisitions

No recent acquisitions found related to Verastem

Verastem Funding History

$16M$68.5M$125.5M$129.4M$134.2M$234.2M

Since Verastem was founded in 2010, it has participated in 8 rounds of funding. In total Verastem has raised $234.2M. Verastem's last funding round was on Feb 2020 for a total of $100.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Feb 2020
$100M
-
Debt
Dec 2019
$4.8M
-
Equity
Feb 2014
$3.9M
-
Equity
Jul 2012
$2M
-
IPO
Jan 2012
$55M

Total Funding: $234.2M

Since Verastem was founded in 2010, it has participated in 8 rounds of funding. In total Verastem has raised $234.2M. Verastem's last funding round was on Feb 2020 for a total of $100.0M

Investments

No recent investments found related to Verastem

Verastem News

August 11, 2020Pharamceutical Technology

Verastem to divest Copiktra rights to Secura Bio for up to $381m

Biopharmaceutical company Verastem has signed a definitive agreement to divest the global commercial ... See more »
August 10, 2020Endpoints News

The duvelisib hot potato is tossed to a new owner as Verastem looks to reorganize around the pipeline

When Infinity put up duvelisib for a no-money-down instant deal, the biotech was looking for a quick ... See more »
August 10, 2020BioSpace

Verastem Oncology Reports Second Quarter 2020 Financial Results and Highlights Recent Company Progress

Announced Path Forward for VS-6766 and Defactinib Combination Following Meeting with FDA Phase 2 Regi... See more »
July 5, 2020BioSpace

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 06, 2020

Verastem, Inc., a biopharmaceutical company committed to developing and commercializing new medicines... See more »
May 28, 2020MarketScreener

Oncology to Present at the Jefferies Virtual Healthcare Conference

(marketscreener.com) Verastem, Inc. , a biopharmaceutical company committed to developing and commerc... See more »

Verastem Press Releases

April 9, 2020GlobeNewswire

Fields Kupka & Shukurov LLP Is Investigating Verastem, Inc. for Potential Breach of Fiduciary Duty Claims.

NEW YORK, April 09, 2020 (GLOBE NEWSWIRE) -- Fields Kupka & Shukurov LLP is investigating potential b... See more »
December 7, 2019centralcharts

Verastem Oncology Presents Phase 2 PRIMO Study Data Evaluating Duvelisib in Relapsed or Refractory Peripheral T-Cell Lymphoma at the American Society of Hematology 2019 Annual Meeting

Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharmaceutical company focused ... See more »
November 25, 2019Business Wire

Verastem Oncology Announces Submission of a Marketing Authorization Application to the European Medicines Agency for COPIKTRA® (duvelisib)

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq:VSTM) (Verastem Oncology or the Company), a biopharma... See more »
November 13, 2019Business Wire

Verastem Oncology Announces Andrei Shustov, M.D., Recipient of 2nd Annual Innovation in Care Award

BOSTON--(BUSINESS WIRE)--Verastem, Inc. (Nasdaq: VSTM), (Verastem Oncology or the Company), a biophar... See more »
October 23, 2019centralcharts

Verastem, Inc. - VSTM Stock Chart Technical Analysis for 10-23-2019

News videos - Verastem, Inc. - VSTM Stock Chart Technical Analysis for 10-23-2019 - Published on 10/2... See more »
April 4, 2019StreetInsider

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc.�(Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercia... See more »
January 7, 2019StreetInsider

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Verastem, Inc.�(Nasdaq: VSTM) (Verastem Oncology or the Company), focused on developing and commercia... See more »

Verastem Videos

Headquarters

117 Kendrick Street Suite 500

Needham, Massachusetts02494

1-781-292-4200

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Verastem is a biopharmaceutical company that researches, develops and commercializes novel therapeutics for the treatment of cancer. Verastem was founded in 2010. Verastem's headquarters is located in Needham, Massachusetts, USA 02494. It has raised 2...

CEO

Verastem's CEO, Brian Stuglik, currently has an approval rating of 66%. Verastem's primary competitors are TG Therapeutics, MEI Pharma & Pharmacyclics.

Website

verastem.com

Frequently Asked Questions about Verastem

  1. When was Verastem founded?

    Verastem was founded in 2010
  2. Who is Verastem's CEO?

    Verastem's CEO is Brian Stuglik
  3. How much revenue does Verastem generate?

    Verastem generates $22M in revenue
  4. How much funding does Verastem have?

    Verastem has historically raised $234.2M in funding
  1. Where is Verastem's headquarters?

    Verastem's headquarters is in Needham Massachusetts, USA
  2. How many employees does Verastem have?

    Verastem has 169 employees
  3. What sector does Verastem operate in?

    Verastem is in Pharmaceuticals, Biotechnology
  4. Who are Verastem's competitors?

    Verastem's top competitors are TG Therapeutics, MEI Pharma, Pharmacyclics